The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity

Toxicology in Vitro

Volumn 27, Issue 2, 2013, Pages 745-751

  Schweikart, Karen ^a   Guo, Liang ^b   Shuler, Zachary ^b   Abrams, Rory ^b   Chiao, Eric T ^b   Kolaja, Kyle L ^b   Davis, Myrtle ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Global Early and Investigative Safety Hoffmann La Roche   (United States)

Author keywords

Cardiotoxicity; Cyclodepsipeptide; In vitro alternatives; Jaspamide; Predictive toxicology; Stem cell derived cardiomyocytes

Indexed keywords

ION CHANNEL; JASPAMIDE; MITOXANTRONE; NSC 613009; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; CELL VIABILITY; CONCENTRATION (PARAMETERS); DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE ANALYSIS; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; PATCH CLAMP; PLURIPOTENT STEM CELL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; DEPSIPEPTIDES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; ION CHANNELS; MYOCYTES, CARDIAC;

CANIS FAMILIARIS; RATTUS;

EID: 84872189323     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.12.005     Document Type: Article

References (26)

1. Anson B.D., Kolaja K.L., Kamp T.J. Opportunities for use of human iPS cells in predictive toxicology. Clin. Pharmacol. Ther. 2011, 89:754-758.
2. Bachmann A., Gutcher I., Kopp K., Brendel J., Bosch R.F., Busch A.E., Gögelein H. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes. Naunyn Schmiedebergs Arch. Pharmacol. 2001, 364:472-478.
3. Bubb M.R., Senderowicz A.M., Sausville E.A., Duncan K.L.K., Korn E. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J. Biol. Chem. 1994, 269:14869-14871.
4. Bubley G., Balk S. Treatment of androgen-independent prostate cancer. Oncologist 1996, 1:30.
5. Crews P., Manes L.V., Boehler M. Jasplakinolide, a cyclodepsipeptide from the marine sponge, Jaspis sp. Tetrahedron Lett. 1986, 27:2797-2800.
6. Fabian I., Shur I., Bleiberg I., Rudi A., Kashman Y., Lishman M. Growth modulation and differentiation of acute myeloid leukemia cells by jaspamide. Exp. Hematol. 1995, 23:583-587.
7. Gala F., D'Auria M.V., De Marino S., Zollo F., Smith C.D., Copper J.E., Zampellaa A. New jaspamide derivatives with antimicrofilament activity from the sponge Jaspis splendans. Tetrahedron 2007, 63:5212-5219.
8. Gala F., D'Auria M.V., De Marino S., Sepe V., Zollo F., Smith C.D., Copper J.E., Zampellaa A. Jaspamides H-L, new actin-targeting depsipeptides from the sponge Jaspis splendans. Tetrahedron 2008, 64:7127-7130.
9. Gala F., D'Auria M.V., De Marino S., Sepe V., Zollo F., Smith C.D., Keller S.N., Zampellaa A. Jaspamides M-P: new tryptophan modified jaspamide derivatives from the sponge Jaspis splendans. Tetrahedron 2009, 65:51-56.
10. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., Chiao E., Kolaja K.L. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 2011, 123:281-289.
11. Karczewski J., Kiss L., Kane S.A., Koblan K.S., Lynch R.J., Spencer R.H. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5. Biochem. Pharmacol. 2009, 77:177-185.
12. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., Kolaja K.L., Swanson B.J., January C.T. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2006-H2017.
13. Marimganti S., Yasmeen S., Fischer D., Maier M.E. Synthesis of jasplakinolide analogues containing a novel w-amino acid. Chem. Eur. J. 2005, 11:6687-6700.
14. Maruoka N.D., Steele D.F., Au B.P.-Y., Dan P., Zhang X., Moore E.D.W., Fedida D. α-Actinin-2 couples to cardiac Kv1.5 channels, regulating current density and channel localization in HEK cells. FEBS Letters 2000, 473:188-194.
15. Mason H.S., Latten M.J., Godoy L.D., Horowitz B., Kenyon J.L. Modulation of Kv1.5 currents by protein kinase A, tyrosine kinase, and protein tyrosine phosphatase requires an intact cytoskeleton. Mol. Pharmacol. 2002, 61:285-293.
16. Nerbonne J.M., Kass R.S. Molecular physiology of cardiac repolarization. Physiol. Rev. 2005, 205:1205-1233.
17. Olson T.M., Alekseev A.E., Liu X.K., Park S., Zingman L.V., Bienengraeber M., Sattiraju S., Ballew J.D., Jahangir A., Terzic A. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 2006, 15:2185-2191.
18. Senderowicz A.M., Kaur G., Sainz E., Charmaine L., Inman W.D., Rodriguez J., Crews P., Malspeis L., Grever M.R., Sausville E.A., Duncan K.L.K. Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton. J. Natl. Cancer Inst. 1995, 87:46-51.
19. Schindler-Horvat J., Fairchild D.G., Hassler C., Tomaszewski J.E., Donohue S.J., Tyson C.A. Toxicity of jasplakinolide (NSC 613009) in rats and dogs. Proc. Amer. Assoc. Cancer Res. 1998, 39:597. (A4063).
20. Slørdal L., Spigset O. Heart failure induced by non-cardiac drugs. Drug Saf. 2006, 29:567-586.
21. Stingl J., Andersen R.J., Emerman T. In vitro screening of crude extracts and pure metabolites obtained from marine invertebrates for the treatment of breast cancer. Cancer Chemother. Pharmacol. 1992, 30:401.
22. Takeuchi H., Ara G., Sausville E.A., Teicher B. Jasplakinolide: interaction with radiation and hyperthermia in human prostate carcinoma and Lewis lung carcinoma. Cancer Chemother. Pharmacol. 1998, 42:491-496.
23. Tannert R., Milroy L.-G., Ellinger B., Hu T.-S., Arndt H.-D., Waldmann H. Synthesis and structure-activity correlation of natural-product inspired cyclodepsipeptides stabilizing F-actin. J. Am. Chem. Soc. 2010, 132:3063-3077.
24. Waldmann H., Hu T.-S., Renner S., Menninger S., Tannert R., Oda T., Arndt H.D. Total synthesis of chondramide C and its binding mode to F-actin. Angew. Chem. Int. Ed. Engl. 2008, 47:6473-6477.
25. Xi B., Yu N., Wang X., Xu X., Abassi Y.A. The application of cell-based label-free technology in drug discovery. Biotechnol. J. 2008, 3:484-495.
26. Yang X., Salas P.J., Pham T.V., Wasserlauf B.J., Smets M.J., Myerburg R.J., Gelband H., Hoffman B.F., Bassett A.L. Cytoskeletal actin microfilaments and the transient outward K+ current in hypertrophied rat ventriculocytes. J. Physiol. 2003, 541:411-421.